首页> 美国卫生研究院文献>Breast Cancer Research : BCR >Invasive lobular carcinoma of the breast: the increasing importance of this special subtype
【2h】

Invasive lobular carcinoma of the breast: the increasing importance of this special subtype

机译:胸膜的侵袭性小叶癌:这种特殊亚型的重要性越来越重要

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Multistep model of the evolution of classic ILC and its morphological variants. A lineage of ‘lobular’ disease evolves from a normal epithelial cell on a background of a loss of E-cadherin expression and function, and key early somatic alterations involving gain of chromosome 1q, loss of 16q, and mutations in PIK3CA, AKT1, or PTEN. The morphological and molecular diversity of in situ and invasive lobular lesions is likely to be a result of the subsequently arising pattern of molecular alterations that drive progression. Atypical lobular hyperplasia (ALH) is distinguishable from lobular carcinoma in situ (LCIS) based on the extent of proliferation within the lobule. Pleomorphic LCIS (PLCIS) and florid LCIS (FLCIS) can emerge either from ALH (presumably) or from classic LCIS (CLCIS), with an increasing level of genomic complexity and the accumulation of mutations in driver genes such as ERBB2, ERBB3, and TP53. Various morphological variants of ILC have also been described (see also Fig. 2), which exhibit either architectural or cytological atypia relative to the classic invasive type, which we imagine being the ‘default’ pathway of evolution. A number of important points to note: (1) the genomic alterations listed may arise during any stage of progression, though are likely to be acquired at the in situ stage, or earlier (e.g. amplification of 11q13 is evident in the in situ stage); (2) it is assumed FLCIS may progress to alveolar, solid, tubulo-lobular variants, or even the pleomorphic type; (3) it is uncommon for invasive tumours to be of a pure variant morphology, with tumours often also exhibiting classic and/or other variant patterns; (4) a variety of molecular alterations have been associated with some of these morphological variants, but these are not necessarily pathognomonic of the architectural variant; and (5) the interplay between the malignant cells and extracellular matrix may also impact the resulting growth pattern. -, loss; +, gain; dotted line, anticipated route of progression; solid line, demonstrated route of progression
机译:经典ILC演化的多步模型及其形态变种。 “小叶”疾病的谱系从常规上皮细胞的丧失的丧失的常规上皮细胞演变,以及涉及染色体增益的关键早期体细胞改变,丧失16Q的丧失和Pik3CA,AKT1或突变PTEN。原位和侵袭性小叶病变的形态学和分子多样性可能是随后产生的分子改变模式的结果驱动进展。基于大叶内的增殖程度,非典型小叶增生(ALH)与原位(LCIS)的分类物质区别化。亲属LCIS(PLCIS)和植物液(FLCIS)可以从ALH(大概)或来自经典的LCIS(CLCIS)中出现,随着基因组复杂性的增加和驾驶员基因如ERBB2,ERBB3和TP53的突变积累。还描述了ILC的各种形态变体(也参见图2),其相对于经典侵入型展示了建筑或细胞学类别,我们想象成为进化的“默认”途径。一些重要要点要注意:(1)所列的基因组改建可能会在进展的任何阶段出现,但可能在原位阶段收购,或之前(例如,11Q13的扩增在原位阶段明显明显) ; (2)假设FLCIS可能对肺泡,固体,微管状变体,甚至是渗透型进行进展; (3)侵入性肿瘤具​​有纯变种形态的纯肿瘤罕见,肿瘤通常也呈现经典和/或其他变体图案; (4)各种分子改变与这些形态变异中的一些有关,但这些不一定是建筑变体的路易面; (5)恶性细胞和细胞外基质之间的相互作用也可能影响所得的生长模式。 -, 失利; +,获得;虚线,预期的进展途径;实线,展示了进展途径

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号